Inclusion Criteria:

1. Age of equal or older than 18 years and not over 75 years with a life expectancy of
at least 12 weeks;

2. Karnofsky performance status (KPS) of ≥70;

3. Histologically or cytologically confirmed HCC;

4. BCLC stage B, solitary lesion (bigger than 5 cm in diameter) with tumor burden less
than 50% of total liver volume;

5. Liver function of Child-Pugh A;

6. Technically unresectable, medically inoperable, or surgery declined by the patient;

7. Normal renal function and adequate bone marrow reservation;

8. Signed informed consent must be obtained prior to any study specific procedure.

Exclusion Criteria:

1. Presence of intrahepatic and/or extrahepatic metastases

2. Previous received systemic therapy for liver cancer;

3. History of radiotherapy to the liver;

4. Indistinct tumor boundary on CT/MRI images;

5. Previous or concurrent malignancies, with the exception of adequately treated basal
cell carcinoma of the skin or in situ carcinoma of the cervix or superficial bladder
tumors [Ta, Tis and T1];

6. History of cardiac disease: congestive heart failure > NYHA class 2, active CAD,
cardiac arrythmias requiring anti-arrhythmic therapy or uncontrolled hypertension
within the last 12 months;

7. Concurrent uncontrolled medical conditions;

8. Pregnancy or breast feeding;

9. Investigational drug therapy outside of this trial during or within 4 weeks of study
entry;

10. Psychiatric or medical unstable conditions that compromise the patient's ability to
give informed consent.